同时靶向EBV裂解期与潜伏期抗原可增强T细胞抗淋巴瘤效力
移植后淋巴瘤中EBV特异性T细胞疗效显著,但移植外EBV阳性恶性肿瘤未能重现。研究用裂解期与潜伏期蛋白共同刺激健康供者及EBV阳性淋巴瘤患者外周血单个核细胞,制备广谱EBV特异性T细胞(BR-EBVSTs)。与T2抗原特异性EBVSTs相比,BR-EBVSTs在NSG小鼠中更快清除自体EBV阳性肿瘤并产生更高水平促炎细胞因子。
要点
- EBV阳性霍奇金淋巴瘤活检组织中可检测到病毒裂解期转录本。
- BR-EBVSTs较T2抗原特异性EBVSTs在NSG小鼠中更快清除自体EBV阳性肿瘤。
- BR-EBVSTs产生更高水平促炎细胞因子,可能重激活免疫抑制性肿瘤微环境。
核心结论
- 裂解期抗原是EBV阳性淋巴瘤临床相关靶点,支持将BR-EBVSTs整合为复发/难治EBV阳性淋巴瘤及其他EBV相关恶性肿瘤的治疗方法。
研究设计与样本
- 用裂解期与潜伏期蛋白共同刺激健康供者和EBV阳性淋巴瘤患者的外周血单个核细胞,制备广谱EBV特异性T细胞(BR-EBVSTs),并与T2抗原特异性EBVSTs比较。
主要发现
- 在EBV阳性霍奇金淋巴瘤活检组织中鉴定出病毒裂解期转录本。
- 与T2抗原特异性EBVSTs相比,BR-EBVSTs在NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ(NSG)小鼠中更快清除自体EBV阳性肿瘤。
- 与T2抗原特异性EBVSTs相比,BR-EBVSTs产生更高水平的促炎细胞因子。
临床怎么用
- 作者认为BR-EBVSTs可作为复发/难治EBV阳性淋巴瘤及其他EBV相关恶性肿瘤的治疗方法进行整合(临床试验注册号:#NCT01555892和#NCT04664179)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The remarkable efficacy of Epstein-Barr virus (EBV)-specific T cells for the treatment of posttransplant lymphomas has not been reproduced for EBV-positive (EBV+) malignancies outside the transplant setting. This is because of, in part, the heterogeneous expression and poor immunogenicity of the viral antigens expressed, namely latent membrane proteins 1 and 2, EBV nuclear antigen 1, and BamHI A rightward reading frame 1 (type-2 [T2] latency). However, EBV lytic cycle proteins are also expressed in certain EBV+ malignancies and, because several EBV lytic cycle proteins are abundantly expressed, have oncogenic activity, and likely contribute to malignancy, we sought and identified viral lytic-cycle transcripts in EBV+ Hodgkin lymphoma biopsies. This provided the rationale for broadening the target antigen-specific repertoire of EBV-specific T cells (EBVSTs) for therapy. We stimulated, peripheral blood mononuclear cells from healthy donors and patients with EBV+ lymphoma with both lytic and latent cycle proteins to produce broad repertoire (BR) EBVSTs. Compared with T2 antigen-specific EBVSTs, BR-EBVSTs more rapidly cleared autologous EBV+ tumors in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice and produced higher levels of proinflammatory cytokines that should reactivate the immunosuppressive tumor microenvironment leading to epitope spreading. Our results confirm that lytic cycle antigens are clinically relevant targets for EBV+ lymphoma and underpin the rationale for integrating BR-EBVSTs as a therapeutic approach for relapsed/refractory EBV+ lymphoma (www.clinicaltrials.gov identifiers: #NCT01555892 and #NCT04664179), as well as for other EBV-associated malignancies.
引用
- Sharma S, Mehta NU, Sauer T, et al. Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv. 2024. PMID: 38640255. doi:10.1182/bloodadvances.2023012183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。